spacer
home > epc > winter 2019 > exploring growth strategies for smaller cros
PUBLICATIONS
European Pharmaceutical Contractor

Exploring Growth Strategies for Smaller CROs

Over the last several decades, clinical trials have increased in size, cost, complexity, and duration, resulting in sponsors becoming increasingly reliant on the outsourcing services of CROs. The number of countries involved in Phase 3 clinical studies doubled between 2005-15, and the number of investigative sites increased by 63%. Simultaneously, the mean number of patients declined by 18%, adding complexity to the study start-up process and putting greater pressure on CROs to deliver (1).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Zac Beda is Director and co-founder at Upsilon Global. As Director of Europe and APAC, he is responsible for supporting business development and bid-defence activities for their small/ mid-sized CRO partners, helping them to win more clinical studies, upscale their operations, and cost-effectively launch clinical programmes in new countries and new regions. Their model is built on a global network of clinical, regulatory, and quality affairs consultants, built over three decades of experience within the healthcare industry. Upsilon Global are currently operational in over 50 countries across six continents.
spacer
Zac Beda
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Nemeras preservative-free multidose eye dropper Novelia® approved for Santens Cosopt® for Glaucoma treatments in 29 European countries

Nemera is pleased to announce that its multidose eye dropper Novelia® has been approved for the preservative-free formulation Cosopt iMulti® (20mg/ml dorzolamide + 5mg/ml timolol eye drops, solution).
More info >>

White Papers

Time lapse photography to demonstrate the potential antimicrobial abilities of Dycem contamination control flooring

Dycem

A defined volume of bioluminescent reporter bacteria was deposited onto 20 mm x 20 mm coupons of Dycem flooring, vinyl tile and ITW Alma tacky mat. Through monitoring of bacterial bioluminescence, metabolic inhibition was observed on all three surfaces however the effect occurred more rapidly on Dycem flooring than on vinyl or ITW Alma. Recovery counts after three hours of exposure to the floor surfaces showed between a 65% and 100% decrease in the number of viable organisms recovered from Dycem flooring compared to controls. On vinyl and ITW Alma flooring, there were slight increases in the number of viable survivors recovered compared to controls. Dycem flooring inhibited the metabolic activity and reduced the number of viable survivors recovered of Salmonella enterica Serovar Typhimurium DT104 pGLITE. It remains unclear as to whether this effect is attributable to the impregnated biocide or rapid drying of the inoculum on this surface.
More info >>

 
Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement